ripekg:evaluation/RIPEA44B073B6366CEDA7 |
prov:used |
ripekg:study-design-evidence/RIPEA44B073B6366CEDA7 |
ripekg:study-design-evidence/RIPEA44B073B6366CEDA7 |
rdf:type |
rdfs:Resource |
ripekg:study-design-evidence/RIPEA44B073B6366CEDA7 |
rdf:type |
owl:Thing |
ripekg:study-design-evidence/RIPEA44B073B6366CEDA7 |
rdf:type |
ripe:IntegrityAssessmentEvidenceIntegrity assessment evidence |
ripekg:study-design-evidence/RIPEA44B073B6366CEDA7 |
rdf:type |
ripe:StudyDesignEvidenceStudy design evidence |
ripekg:study-design-evidence/RIPEA44B073B6366CEDA7 |
rdf:type |
tido:Evidence |
ripekg:study-design-evidence/RIPEA44B073B6366CEDA7 |
prov:wasGeneratedBy |
ripekg:evidence-aggregation/RIPEA44B073B6366CEDA7 |
ripekg:study-design-evidence/RIPEA44B073B6366CEDA7 |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEA44B073B6366CEDA7 |
ripekg:study-design-evidence/RIPEA44B073B6366CEDA7 |
ripe:concerns |
ripekg:work/10.1111%2Fjsr.14373Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study |
ripekg:study-design-evidence/RIPEA44B073B6366CEDA7 |
ripe:recruitmentEndDate |
24-04-2019 |
ripekg:study-design-evidence/RIPEA44B073B6366CEDA7 |
ripe:recruitmentEndDateExtractionRationale |
Results: 'between 7 April 2016 and 24 April 2019, to receive pitolisant (n = 242) or placebo (n = 119), which represented the FAS'. |
ripekg:study-design-evidence/RIPEA44B073B6366CEDA7 |
ripe:recruitmentStartDate |
07-04-2016 |
ripekg:study-design-evidence/RIPEA44B073B6366CEDA7 |
ripe:recruitmentStartDateExtractionRationale |
Trial Registration Information: 'date of first patient dosed 7 April 2016'. |
ripekg:study-design-evidence/RIPEA44B073B6366CEDA7 |
ripe:studyEndDateExtractionRationale |
No explicit study end date found. The randomised phase ended at week 12. |
ripekg:study-design-evidence/RIPEA44B073B6366CEDA7 |
tido:supports |
ripekg:integrity-assessment-hypothesis/RIPEA44B073B6366CEDA7-human-2-2 |
ripekg:study-design-evidence/RIPEA44B073B6366CEDA7 |
tido:supports |
ripekg:integrity-assessment-hypothesis/RIPEA44B073B6366CEDA7-inspectai-2-2 |